Trial
NCT02176486
Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Takeda
Collaborators
—
Condition
Lupus Nephritis
Intervention
Ixazomib
Why stopped
Insufficient enrollment, no safety or efficacy concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-04-08